BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26927239)

  • 1. Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors.
    Chao A; Wang TH
    Taiwan J Obstet Gynecol; 2016 Feb; 55(1):3-8. PubMed ID: 26927239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.
    Fristedt Duvefelt C; Lub S; Agarwal P; Arngården L; Hammarberg A; Maes K; Van Valckenborgh E; Vanderkerken K; Jernberg Wiklund H
    Oncotarget; 2015 Aug; 6(24):20621-35. PubMed ID: 26036313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
    Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
    Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
    Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
    J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification.
    Pundir S; Vu HY; Solomon VR; McClure R; Lee H
    Cancer Res; 2015 Oct; 75(19):4164-75. PubMed ID: 26238784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
    Toscani D; Palumbo C; Dalla Palma B; Ferretti M; Bolzoni M; Marchica V; Sena P; Martella E; Mancini C; Ferri V; Costa F; Accardi F; Craviotto L; Aversa F; Giuliani N
    J Bone Miner Res; 2016 Apr; 31(4):815-27. PubMed ID: 26551485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
    Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
    Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-Glycoprotein Inhibition Sensitizes Human Breast Cancer Cells to Proteasome Inhibitors.
    Deshmukh RR; Kim S; Elghoul Y; Dou QP
    J Cell Biochem; 2017 May; 118(5):1239-1248. PubMed ID: 27813130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
    Wu T; Chen W; Zhong Y; Hou X; Fang S; Liu CY; Wang G; Yu T; Huang YY; Ouyang X; Li HQ; Cui L; Yang Y
    Mol Cancer Ther; 2017 Apr; 16(4):717-728. PubMed ID: 27903750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
    Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
    Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating MCF7 breast cancer cell with proteasome inhibitor Bortezomib restores apoptotic factors and sensitizes cell to Docetaxel.
    Mehdizadeh K; Ataei F; Hosseinkhani S
    Med Oncol; 2021 Apr; 38(6):64. PubMed ID: 33904968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
    Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
    Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
    Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
    Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers.
    Thapa RK; Nguyen HT; Jeong JH; Shin BS; Ku SK; Choi HG; Yong CS; Kim JO
    Nanomedicine; 2017 Apr; 13(3):885-896. PubMed ID: 27993720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery, Development, and clinical applications of bortezomib.
    Jung L; Holle L; Dalton WS
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
    Arkwright R; Pham TM; Zonder JA; Dou QP
    Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibitors.
    Teicher BA; Tomaszewski JE
    Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo.
    Jarauta V; Jaime P; Gonzalo O; de Miguel D; Ramírez-Labrada A; Martínez-Lostao L; Anel A; Pardo J; Marzo I; Naval J
    Cancer Lett; 2016 Nov; 382(1):1-10. PubMed ID: 27565383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.